EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR-Cas9 in Precision Oncology: Unraveling Resistance Mechanisms and Redefining Molecular Targeted Cancer Therapy

Muhammad Osama, Ayesha Ghafoor, Toheed Fatima, Muhammad Shaharyar, Khadija Javed, Zainab Bibi, Bisma, Farwa Shafique, Maryam Jameel

Journal of Cancer Biomoleculars and Therapeutics · 08.04.2026 · 3 (2) · 1-12

DOI: 10.62382/jcbt.v3i2.109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Biomoleculars and Therapeutics, online erschienen am 08.04.2026. Verfasst von Muhammad Osama und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer therapeutics have evolved from standard cytotoxic chemotherapy to specialized molecular targeted therapies, which scientists now develop using purposeful design methods. The treatments function by targeting molecular changes that lead to cancer development through epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), B-Raf proto-oncogene, serine/threonine kinase (BRAF) pathway mutations. Targeted therapies have achieved outstanding results, but drug resistance development creates a major obstacle that restricts their treatment success in medical practice. Scientists now understand genetic networks that control treatment outcomes and drug resistance because of major developments in Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9 (CRISPR-Cas9) genome-editing technology. This review provides a full examination of molecular targeted cancer therapy development and resistance mechanisms, and CRISPR-Cas9 applications for discovering new cancer cell weaknesses. It explains CRISPR-based functional genomic screens, which identify genes and pathways responsible for drug resistance, to develop new treatment approaches and explore the ethical aspects and technical obstacles, and future development possibilities for combining artificial intelligence with omics data and CRISPR precision oncology. The scientific breakthroughs create a new era for personalized cancer treatment, which unites genetic discoveries with medical practice. Beyond identifying oncogenic drivers, CRISPR-based functional genomics expands the therapeutic paradigm toward systematic interrogation of resistance circuits and synthetic lethal interactions. This shift redefines molecular targeted therapy from static inhibition of single driver mutations to dynamic targeting of adaptive survival networks that sustain tumor progression under therapeutic pressure. The medical field is experiencing a new period of individualized cancer treatment through these technological developments, which connect genetic discoveries to their clinical applications.

Zitieren

APA

Osama, M., Ghafoor, A., Fatima, T., Shaharyar, M., Javed, K., Bibi, Z., Bisma, Shafique, F., & Jameel, M. (2026). CRISPR-Cas9 in Precision Oncology: Unraveling Resistance Mechanisms and Redefining Molecular Targeted Cancer Therapy. Journal of Cancer Biomoleculars and Therapeutics, 3(2), 1-12. https://doi.org/10.62382/jcbt.v3i2.109

Vancouver

Osama M, Ghafoor A, Fatima T, Shaharyar M, Javed K, Bibi Z, et al. CRISPR-Cas9 in Precision Oncology: Unraveling Resistance Mechanisms and Redefining Molecular Targeted Cancer Therapy. Journal of Cancer Biomoleculars and Therapeutics. 2026;3(2):1-12. doi:10.62382/jcbt.v3i2.109

BibTeX
@article{Osama2026,
  author = {Osama, Muhammad and Ghafoor, Ayesha and Fatima, Toheed and Shaharyar, Muhammad and Javed, Khadija and Bibi, Zainab and Bisma and Shafique, Farwa and Jameel, Maryam},
  title = {CRISPR-Cas9 in Precision Oncology: Unraveling Resistance Mechanisms and Redefining Molecular Targeted Cancer Therapy},
  journal = {Journal of Cancer Biomoleculars and Therapeutics},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {1--12},
  doi = {10.62382/jcbt.v3i2.109}
}
Kostenlos starten →